MIT Sloan logo

Welcome to the new MIT Golub Center for Finance and Policy site section!

Smart. Open. Grounded. Inventive. Read our Ideas Made to Matter.

MBA

Through intellectual rigor and experiential learning, this full-time, two-year MBA program develops leaders who make a difference in the world.

Master of Finance

A rigorous, hands-on program that prepares adaptive problem solvers for premier finance careers.

Master of Business Analytics

A 12-month program focused on applying the tools of modern data science, optimization and machine learning to solve real-world business problems.

Leaders for Global Operations

Earn your MBA and SM in engineering with this transformative two-year program.

Master of Science in Management Studies

Combine an international MBA with a deep dive into management science. A special opportunity for partner and affiliate schools only.

PhD

A doctoral program that produces outstanding scholars who are leading in their fields of research.

Undergraduate

Bring a business perspective to your technical and quantitative expertise with a bachelor’s degree in management, business analytics, or finance.

System Design & Management

A joint program for mid-career professionals that integrates engineering and systems thinking. Earn your master’s degree in engineering and management.

Integrated Design & Management

An interdisciplinary program that combines engineering, management, and design, leading to a master’s degree in engineering and management.

Executive Programs

MIT Sloan Fellows MBA

A full-time MBA program for mid-career leaders eager to dedicate one year of discovery for a lifetime of impact.

MIT Executive MBA

This 20-month MBA program equips experienced executives to enhance their impact on their organizations and the world.

Executive Education

Non-degree programs for senior executives and high-potential managers.

Visiting Fellows

A non-degree, customizable program for mid-career professionals.

recent

GCFP Director and Executive Director in American Banker

Liquidity Risk (Mis)Management: The Failure of Silicon Valley Bank and the Liability-Driven Investment Episode in UK Gilt Markets

Duration Gap Disclosure: A Modest Proposal to Prevent Another SVB

MIT Golub Center for Finance and Policy

Estimating Probabilities of Success of Vaccine and Other Anti-Infective Therapeutic Development Programs

By

MIT GCFP - Briefs and Blogs

May 27, 2020

In a paper published in the Harvard Data Science Review on May 14, 2020, the co-director of GCFP, Andrew Lo, along with his co-authors Kien Wei Siah and Chi Heem Wong, estimate the probability of success (PoS) of vaccines and therapeutics. Analyzing 2,544 vaccine programs and 6,829 nonvaccine programs targeting infectious diseases, they find:

“The overall estimated PoS for an industry-sponsored vaccine program is 39.6%, and 16.3% for an industry-sponsored anti-infective therapeutic. … Non-industry-sponsored vaccine and nonvaccine development programs have lower overall PoSs: 6.8% and 8.2%, respectively.”

This paper is very informative when making policy decisions about our response to the COVID-19 pandemic.

Read the full text of the paper here